Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03744403 · ClinicalTrials.gov registry record · Phase 1
A Study of CS1001 in Subjects with Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by CStone Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03744403 is a Phase 1 study of Advanced Solid Tumors that has completed, run by CStone Pharmaceuticals. The registered enrollment target is 24 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03744403, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by CStone Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced solid tumors.
Conditions Studied
Interventions
- DRUG CS1001
Study Locations (1)
Texas
- NEXT Oncology - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-12-04 |
| Est. Completion | 2021-07-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03744403
The ClinicalTrials.gov registry entry for NCT03744403 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (88% lower). The listed sponsor is CStone Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which CS1001 is the first listed.
NCT03744403 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03744403 about?
NCT03744403 is a clinical study titled "A Study of CS1001 in Subjects with Advanced Solid Tumors". This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced solid tumors.
What is the current status of trial NCT03744403?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-12-04. Estimated completion is 2021-07-21.
What conditions does trial NCT03744403 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT03744403?
The interventions under investigation include: CS1001 (DRUG).
Who is sponsoring clinical trial NCT03744403?
This trial is sponsored by CStone Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03744403 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.